latest stock market, financial and business news. Get stock market quotes, personal finance advice, company news and more.

Bank profits past their peak as mortgage war takes toll

Save articles for later Add articles to your saved list and come back to them any time. Bank profits have peaked and are set to come under further pressure from stiff competition in home loans, investors say, as the market prepares for updates from two key protagonists in the mortgage war: ANZ Bank and Commonwealth Bank. After results this week […]

Read more

Oil Futures Settle Sharply Lower For 2nd Straight Day

Crude oil prices fell sharply on Wednesday, sliding for a second straight session, amid rising concerns about the outlook for energy demand. Data showing a sharp jump in crude oil inventories in the U.S. also weighed on oil prices. Oil prices were also hurt by a firm dollar. The dollar rose against several major currencies today amid uncertainty about the […]

Read more

Roche: Elevidys Trial In DMD Fails To Meet Primary Endpoint, But Shows Positive Efficacy Outcomes

Swiss drug major Roche Holding AG (RHHBY) announced Tuesday that EMBARK trial of Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy or DMD failed to reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints. In the global, randomised, double-blind Phase 3 EMBARK study, Elevidys-treated boys aged 4-7 years with DMD showed an increase on the North […]

Read more

Treasuries Move Sharply Lower Ahead Of Key Economic Data

After ending the previous session little changed, treasuries moved sharply lower over the course of the trading day on Wednesday. Bond prices came under pressure in early trading and saw further downside as the day progressed. As a result, the yield on the benchmark ten-year note, which moves opposite of its price, surged 11.3 basis points to 4.593 percent. The […]

Read more

Merck Reveals Positive Results From Phase 3 KEYTRUDA Trials In Various Cancers

Drug major Merck & Co., Inc. (MRK) Friday announced positive results of Phase 3 trials with its anti-PD-1 therapy KEYTRUDA (pembrolizumab) in various cancers. In the Phase 3 KEYNOTE-756 trial, KEYTRUDA in combination with chemotherapy showed statistically significant improvement in pathological complete response or pCR rate as neoadjuvant therapy versus chemotherapy in high-risk, early-stage ER+/HER2- breast cancer. Separately, Merck announced […]

Read more
1 2 3 4 6